Compare Amylx Pharmaceuticals Inc (AMLX) vs Franklin Resources, Inc. (BEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Franklin Resources, Inc. — how do they compare? Amylx Pharmaceuticals Inc trades at $17.37 (market cap $1.98B), while Franklin Resources, Inc. trades at $33.2 (market cap $17.41B). The key difference: Franklin Resources, Inc. is far larger — about 8.8× Amylx Pharmaceuticals Inc's market cap, and Franklin Resources, Inc. pays a 3.94% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | BEN | |
|---|---|---|
Market Cap | $1.98B | $17.41B |
Sector | Health | Financials |
52-Week High | $18.70 | $34.44 |
52-Week Low | $7.64 | $21.18 |
Enterprise Value | $1.70B | $29.23B |
Dividend Yield | — | 3.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Franklin Resources (BEN) trades at $33.50, down 0.53% on the day, with a bullish technical outlook from moving averages and a consensus price target of $34.17. The company reported Q1 2026 EPS of $0.71, beating expectations of $0.55, and maintains strong profitability with an 80.72% gross margin. Recent news highlights its inclusion in dividend stock lists and a Zacks upgrade to Strong Buy on June 23, 2026, amid steady asset growth to $1.79 trillion AUM in June.
BEN presents a mixed outlook with solid earnings beats and dividend appeal offset by weak cash flow trends and modest growth. Upside is supported by analyst optimism and technical momentum, but risks include net cash outflows and competitive pressures in asset management. The stock's valuation at a P/E of 25.57 requires sustained earnings growth to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Franklin Resources, Inc.
Franklin Resources provides investment services for individual and institutional investors. At the end of August 2022, Franklin had $1.388 trillion in managed assets, composed primarily of equity (32%), fixed-income (38%), multi-asset/balanced (10%) funds, alternatives (16%), and money market funds (4%). Distribution tends to be weighted more toward retail investors (49% of AUM) investors, as opposed to institutional (49%) and high-net-worth (2%) clients. Franklin is also one of the more global firms of the U.S.-based asset managers with more than 35% of its AUM invested in global/international strategies and 25% of managed assets sourced from clients domiciled outside the United States.
Read more on BEN →
